Intellectual Property

Our research and development is supported by a broad intellectual property portfolio. We currently own or have exclusive licenses to over 30 patents and 380 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. We also have non-exclusive rights to a portfolio of patents and patent applications that support our core intellectual property. We believe our intellectual property collectively represents one of the strongest portfolios in the field.

Our success will likely depend upon our ability to preserve our proprietary technologies and operate without infringing the proprietary rights of other parties. However, we may rely on certain proprietary technologies and know-how that are not patentable. We protect our proprietary information, in part, by the use of confidentiality agreements with our employees, consultants and certain of our contractors.

We maintain a disciplined patent policy and, when appropriate, seek patent protection for inventions in our core technologies and in ancillary technologies that support our core technologies or which we otherwise believe will provide us with a competitive advantage. We pursue this strategy by filing patent applications for discoveries we make, either alone or in collaboration with scientific collaborators and strategic partners. Typically, although not always, we file patent applications both in the United States and in select international markets. In addition, we plan to obtain licenses or options to acquire licenses to patent filings from other individuals and organizations that we anticipate could be useful in advancing our research, development and commercialization initiatives and our strategic business interests.

The following table identifies the issued patents we own or license that we believe currently support our technology platform.

Owned by Advanced Cell Technology, Inc.

Number Patent Country Filing Date Issue Date Title
6,808,704 US 09/06/00 10/26/04 Method for Generating Immune-Compatible Cells and Tissues Using Nuclear Transfer Techniques
518191 New Zealand 10/13/00 05/10/04 Method of Differentiation of Morula or Inner Cell Mass Cells and Method of Making Lineage-Defective Embryonic Stem Cells
516236 New Zealand 12/18/01 04/07/05 Cytoplasmic Transfer to De-Differentiate Recipient Cells

University of Massachusetts Exclusive License to Advanced Cell Technology, Inc.

Number Patent Country Filing Date Issue Date Title
6,235,970 US 09/22/97 05/22/01 CICM Cells and Non-Human Mammalian Embryos Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
6,235,969 US 07/03/97 05/22/01 Cloning Pigs Using Donor Nuclei from Non-Quiescent Differentiated Cells
6,215,041 US 01/08/98 04/10/01 Cloning Using Donor Nuclei from a Non-Quiescent Somatic Cells
6,156,569 US 08/04/97 12/05/00 Prolonged Culturing of Avian Primordial Germ Cells (PGCs) Using Specific Growth Factors, Use Thereof to Produce Chimeric Avians
5,994,619 US 12/16/96 11/30/99 Production of Chimeric Bovine or Porcine Animals Using Cultured Inner Cell Mass Cells
5,945,577 US 01/10/97 08/31/99 Cloning Using Donor Nuclei from Proliferating Somatic Cells
5,905,042 US 04/01/96 05/18/99 Cultured Inner Cell Mass Cell Lines Derived from Bovine or Porcine Embryos
521426 New Zealand 03/26/01 11/11/04 Prion-Free Transgenic Ungulates
521026 New Zealand 02/26/01 01/13/05 Production of Mammals which Produce Progeny of a Single Sex
518365 New Zealand 10/27/00 08/12/04 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
517609 New Zealand 09/14/00 06/08/04 Embryonic or Stem-Like Cell Lines Produced by Cross Species Nuclear Transplantation and Method for Enhancing Embryonic Development by Genetic Alteration of Donor Cells or by Tissue Culture Conditions
519346 New Zealand 05/10/00 06/08/04 Embryonic or Stem-Like Cell Lines Produced by Cross Species Nuclear Transplantation
759322 Australia 03/02/99 07/24/03 Embryonic or Stem-Like Cell Lines Produced by Cross Species Nuclear Transplantation
506808 New Zealand 03/02/99 03/29/04 Embryonic or Stem-Like Cell Lines Produced by Cross Species Nuclear Transplantation
502713 New Zealand 08/04/98 01/05/04 Production of Avian Embryonic Germ (EG) and Embryonic Stem (ES) Cell Lines by Prolonged Culturing of PGCs Use Thereof of Cloning and Chimerization
502712 New Zealand 08/04/98 05/12/03 Avian Primordial Germ Cell (PGC) Cell Line and a Method for Long Term Culturing Thereof
742840 Australia 07/01/98 08/01/02 Cloning Pigs Using Donor Nuclei from Differentiated Cells
502124 New Zealand 07/01/98 05/12/03 Cloning Pigs Using Donor Nuclei from Differentiated Cells
742363 Australia 01/05/98 01/03/02 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells
334016 New Zealand 07/28/97 12/07/00 Embryonic or Stem-Like Cell Lines Produced by Cross Species Nuclear Transplantation
717529 Australia 03/24/97 07/13/00 Cultured Inner Cell Mass Cell Lines Derived from Ungulate Embryos
126416 Israel 03/24/97 09/21/04 Cultured Inner Cell Mass Cell Lines Derived from Ungulate Embryos
332159 New Zealand 03/24/97 06/08/00 Cultured Inner Cell Mass Cell Lines Derived from Ungulate Embryos

Genzyme Transgenics Corp. Exclusive License to Advanced Cell Technology, Inc.

Number Patent Country Filing Date Issue Date Title
6,580,017 US 04/23/99 06/17/03 Methods of Reconstructed Goat Embryo Transfer
6,528,699 US 03/22/01 03/04/03 Transgenically Produced Non-Secreted Proteins
517930 New Zealand 09/27/00 05/10/04 Methods of Producing Cloned and Transgenic Mammals
88117 Singapore 10/16/00 03/31/04 Methods of Producing a Target Molecule in a Transgenic Animal and Purification of the Target Molecule
518263 New Zealand 10/16/00 07/05/04 Methods of Producing a Target Molecule in a Transgenic Animal and Purification of the Target Molecule

Infigen Non-Exclusive License to Advanced Cell Technology,Inc.

Number Patent Country Filing Date Issue Date Title
6,700,037 US 12/28/00 03/02/04 Method of Cloning Porcine Animals
6,680,199 US 05/22/00 01/20/04 In Vitro Activation of Mammalian Oocytes and Use in Cloning Procedures
6,603,059 US 10/16/00 08/05/03 Ungulates Produced By Sequential Nuclear Transfer
6,395,958 US 07/15/99 05/28/02 Method of Producing a Polypeptide In an Ungulate
6,258,998 US 11/24/98 07/10/01 Method of Cloning Porcine Animals
6,194,202 US 03/04/96 02/27/01 Parthenogenic Oocyte Activation
6,077,710 US 10/21/98 06/20/00 Parthenogenic Oocyte Activation
6,011,197 US 01/28/99 01/04/00 Method of Cloning Bovines Using Reprogrammed Non-Embryonic Bovine Cells
5,843,754 US 06/06/95 12/01/98 Parthenogenic Bovine Oocyte Activation
5,496,720 US 02/10/93 03/05/96 Parthenogenic Oocyte Activation
5,453,366 US 03/15/93 09/26/95 Method of Cloning Bovine Embryos
5,374,544 US 01/15/92 12/20/94 Mutated Skeletal Actin Promoter
4,994,384 US 10/27/87 02/19/91 Multiplying Bovine Embryos